Compare Celestica Inc (CLS) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs Charles River Laboratories Intl. Inc — how do they compare? Celestica Inc trades at $336 (market cap $39.16B), while Charles River Laboratories Intl. Inc trades at $286.32 (market cap $13.46B). The key difference: Celestica Inc is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Celestica Inc nearer its low. Which is the better fit depends on your goals.
| CLS | CRL | |
|---|---|---|
Market Cap | $39.16B | $13.46B |
Sector | Technology | Health |
52-Week High | $472.40 | $282.00 |
52-Week Low | $181.34 | $145.57 |
Enterprise Value | $39.44B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLS trades at $327.15, up 3.99% in 24 hours, with a bearish technical signal but strong fundamentals including a 52.69% ROE and Q2 2026 EPS of $2.54 beating estimates. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, though this may cause near-term dilution.
The outlook is positive with analyst consensus at Buy (64.29%) and a $466.50 price target, driven by AI demand and partnerships. Risks include equity dilution and premium valuation, but growth catalysts from hyperscaler investments support long-term upside.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
